Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 4Neoplasms 3Lymphoma, T-Cell, Peripheral 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, B-Cell 2Recurrence 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Rituximab 8dacetuzumab 5blinatumomab 5ibrutinib 3Cyclophosphamide 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Vincristine 2Prednisone 2Lutetium 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2venetoclax 1sepantronium 1pomalidomide 1obinutuzumab 1fludarabine 1ficlatuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1amonafide 1Vorinostat 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphatic Diseases × denileukin diftitox × Clear all
NCT01401530 2018-11-23

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 1 Completed
13 enrolled 18 charts
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡